Abstract: Disabling behavioral inactivity is a prominent symptom of a number of psychiatric disorders, most notably, major depressive illness. The neurobiology of these inactive states is currently believed to involve alterations in central serotonergic, noradrenergic or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain α 1 -adrenoceptors stimulated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems and plays a critical role in behavioral activation and depression. The present review covers the evidence for this system and includes findings that brain α 1 -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and are restored by a number of antidepressants. This "EPI-α 1 system" may therefore represent a new target system for disabling inactivity.
One of the cardinal symptoms of major depressive illness is a loss of interest or pleasure in virtually all activities. There is broad agreement that depressed patients are most deficient in positively-motivated behaviors which are behaviors associated or conditioned to positive reinforcers. Studies of these patients in the field have indicated that they suffer a profound loss of "active leisure" which refers to rewarding activities of a sustained and effortful nature such as social interaction, hobbies, sports, entertainment and the like [1, 2] . Noneffortful forms of gratification do not appear to be as severely affected since depressives are known to spend prolonged periods of time in passive activities, such as watching television, and have recently been found to experience a greater than normal euphoric response to amphetamine [3] .
system that may broadly regulate these structures and may be disturbed during depression is the epinephrine-stimulated α 1 -adrenoceptor system (EPI/α 1 -system). This putative system consists of a subgroup of α 1 -receptors, which receives epinephrine (EPI) rather than norepinephrine (NE) as its endogenous neurotransmitter and may extend throughout the CNS. The EPI/α 1 -system has been shown to be essential for active behavior in a variety of conditions [9] . Furthermore, it appears to be a prominent factor regulating three major monoaminergic systems, the noradrenergic, dopaminergic and serotonergic, which are themselves key factors in positively-motivated behavior. That the EPI/α 1 -system is impaired in depression is suggested by findings of desensitization or down-regulation of central α 1 -receptors and reduced CSF levels of EPI in these patients. What follows is a review of the research supporting these conclusions. In order to understand how these behaviors are lost in depression, it is first necessary to understand how they are normally regulated. Positively-motivated behaviors are known to be elaborated by a complex network of structures that extends throughout the neuraxis and includes prefrontal cortical, hypothalamic and thalamic areas that modulate basal ganglia, midbrain, lower brainstem and spinal motor control systems [4] . These areas integrate information on the state of arousal, circadian cycle, energy balance, deprivation level, sexual and other motivations, perceptions and cognitions with processes controlling motor output. Which of these regions is impaired or inhibited in depression is not yet clearly understood although reductions in functional activity have consistently been reported in central dopaminergic systems [5, 6] and in portions of the prefrontal cortex [7, 8] .
ROLE OF BRAIN α 1 -ADRENOCEPTOR ACTIVITY IN BEHAVIORAL ACTIVITY
Brain α 1 -adrenoceptors have long been known to influence motor and exploratory activity (reviewed in [10, 11] ). The degree of this influence, however, was not fully appreciated until recent systematic studies were undertaken by the present authors on the effects of selective adrenergic receptor antagonists on exploratory behavior of mice and rats in a novel cage.
Novel cages (of the same type as the home cage) are relatively nonthreatening environments that elicit sustained exploration (1-2 hr) in rodents and are positively reinforcing in that animals will work to gain access to novel stimuli and will preferentially visit novel areas [12] . Although these cages probably also induce some anxiety, the exploration that they elicit is very vigorous and is not increased by anxiolytics. Therefore exploratory behavior of a novel cage can be used as an initial test of sustained, effortful, positively-motivated gross motor activity with which to screen various treatments.
nocturnal activity compared to wild type controls [23] . Furthermore, a recently developed α 1D -deficient mouse mutant has been found to show reduced rearing (but not ambulation) in a novel chamber and reduced wheel running in the home cage [24] . Using this measure it was found that blockade of brain α 1 -receptors in mice and rats with intraventricular (ivt.) terazosin, a soluble α 1 -antagonist, produced a total dosedependent abolition of all active behavior and movement [10] . Blockade of central α 2 -, β 1 -, or β 2 -adrenoceptors did not produce this behavioral change. Furthermore there was a near perfect correlation (r = 0.96) between the number of central α 1 -receptors blocked by terazosin, as measured by the ex vivo binding of [ 3 H]prazosin in brain tissue, and the loss of behavioral activity in the novel cage [13] . In addition, the terazosin-induced inactivity could be completely reversed by coinjection of an α 1 -agonist indicating that the behavioral change was not due to a nonspecific inhibitory or toxic effect of the antagonist.
It should be noted that the stimulation of active behavior by α 1 -agonists has a number of puzzling characteristics that are reminiscent of rate-dependency. Thus, these agonists will stimulate active behavior if animals are tested under conditions that make for low activity and low stress or after depletion of brain catecholamines but will reduce activity under high-active, high-stress or nondepleted conditions [25] [26] [27] . Furthermore, whereas low to moderate doses of α 1 -agonists produce a dose-dependent increase in motor activity, high doses produce a fall-off or actual depression of activity even in the low-active condition. In addition, low doses of α 2 -adrenoceptor agonists, which induce an opposing hyperpolarization, can enhance the behavioral stimulation produced by α 1 -agonists [28] . Since, α 1 -receptors produce depolarization in their host neurons in most brain regions [29] , this rate-dependency has suggested that strong stimulation of these receptors produces a depolarization blockade which impedes nerve impulse generation and inhibits active behavior [28, 30] . This effect is assumed to be precluded or mitigated by low-active, lowstress conditions, depletion of brain catecholamines, and by hyperpolarizing α 2 -agonists.
Since α 1 -agonists given alone centrally had long been known to stimulate locomotion and exploratory behavior [14] , these findings indicated that, in the intact brain, α 1 -receptor activity is necessary and sufficient to produce activation of these behaviors in rodents.
The activating effect of central α 1 -receptors on motor activity is not simply the result of awakening the rats who normally sleep during the day. Terazosin-treated inactive mice and rats were not found to be sedated or hypotensive, but instead had normal righting-, and pain reflexes and sufficient muscular tension to support themselves for prolonged intervals (30 sec) on a taut horizontal wire [10] . Animals made similarly ataxic with a benzodiazepine fall right off the wire. Although prazosin has been found to block the arousing effect of central α 1 -agonists [15] , it does not produce an increase in slow-wave sleep by itself [16] . Furthermore, others have shown that it is possible to separate the arousing from the motor activity stimulating effects of central α 1 -receptors in that stimulation of α 1 -receptors in basal forebrain regions in rats produces EEG and behavioral arousal but does not stimulate motor activity [17] whereas stimulation of these receptors in brainstem regions (see below) produces vigorous exploratory behavior of familiar surroundings.
The possibility of depolarization blockade occurring with intense stimulation of central α 1 -receptors has important implications for mechanisms of action of various psychostimulants since many of these drugs act on behavior, in part, via α 1 -receptors (see below) and also produce ratedependent stimulation of active behavior [31] .
BRAIN LOCALIZATION OF BEHAVIORALLY-ACTIVATING α 1 -RECEPTORS
Where in the brain these receptors act to stimulate behavior has recently been studied in mice and rats [32] by determining where terazosin microinjection induces immobility in the novel cage test and where α 1 -agonists stimulate exploratory activity in a low activity environment (home cage). Six or seven brain regions have been found in the mouse brain including the locus coeruleus (LC), periaqueductal gray in the vicinity of the dorsal raphe (PAG/DR), vermis lobe of the cerebellum, nucleus accumbens (NAc), medial preoptic area (MPOA), motor cortex and probably C1 nucleus of the ventrolateral medulla. These regions represent or project to motor, motivational and arousal systems, and extend throughout the neuraxis.
The subtype of α 1 -receptor that primarily mediates behavioral activation appears to be the 1B. Three subtypes of α 1 -adrenoceptors are known to be expressed in the mammalian CNS, the α 1A, α 1B and α 1D [18, 19] . Using six different α 1 -receptor antagonists each having different affinities for these receptors, we showed that the ability of these drugs, given ivt., to block behavioral activity to novelty is highly correlated with their binding affinities for the cloned α 1B receptor (r = 0.89) but not the cloned α 1A (r = 0.30) or α 1D receptors (r = 0.13). Other workers have shown that the α 1B -receptor is also the subtype involved in the reversal of narcolepsy in dogs by stimulants [20] .
The most marked effects in mice were found in the LC, PAG/DR and cerebellum with the animals that were injected in these areas spending 51, 58 and 44%, respectively, of a 10 min test completely immobile as compared to 28% for the NAc, 33% for the MPOA and 17% for the motor cortex. Injection of terazosin in the 4 th ventricle produced the greatest degree of immobility (80% of test) in both mice and rats probably by acting simultaneously on the LC, DR and cerebellum. The immobility induced by terazosin in these regions was reversed by coinjection of the α 1 -agonists, 6-fluoronorepinephrine (6FNE) and phenylephrine (PE), and However, α 1A -and α 1D -receptors are also probably involved since, knockout of the α 1B -receptor in mice has not usually been found to reduce behavioral activity in novel surroundings or in the home cage [21] (but see [22] ). This resistance may be due to compensation by the remaining two α 1 -receptor subtypes since mice with combined knockout of both the α 1B -and α 1A -receptor have a markedly diminished injection of these agonists alone in these brain regions was found to stimulate behavioral activation in the home cage test.
small amounts of EPI are stored in the brain, its extracellular level in the hypothalamus and LC as measured by microdialysis and push-pull cannula is nearly as high as that of NE [37] [38] [39] , and its metabolite, metanephrine (MN), is present at high concentration in the CSF [40] suggesting that it is a major brain neurotransmitter.
The location of "motoric" α 1 -receptors in the LC was recently confirmed in rats by mapping the sites of terazosin injection and by the use of the noradrenergic neurotoxin, DSP4, pretreatment with which abolished the behavioral inhibitory effect of terazosin and the behavioral excitatory effect of PE in this nucleus [33] .
Although EPI was long known to be a neurotransmitter for brainstem α 2 -adrenoceptors [41] , it had been found that its depletion by synthesis inhibition or genetic factors markedly up-regulated the number of brainstem α 1 -receptors [42] . This suggested that EPI tonically stimulates brainstem motoric α 1 -receptors. In support of this notion it has been found that in at least 4 out of the above 6 brain regions that contain these receptors (LC, MPOA, PAG/DR, NAc), there is either a significant degree of innervation by PNMTpositive nerve endings [43] or evidence of substantial levels of EPI and its metabolite, MN, during heightened behavioral activation [44] . Furthermore, smaller amounts of EPI have been detected in the vermis cerebellum and cerebral cortex as well [35] . In addition mice deficient in both EPI and NE as a result of disruption of the dopamine β-hydroxylase gene were shown to be about half as active as wild type controls in a novel test chamber [45] , whereas rats strains with relatively high levels of brainstem PNMT and EPI (Fischer 344 and spontaneous hypertensive) have higher motor activity responses to novelty [46] and to the forced swimming test [47] than strains with lower levels (Buffalo, Wistar-Kyoto).
No immobility to terazosin was found in 17 other brain regions including the substantia nigra (SN), corpus striatum, ventral tegmental area (VTA), prefrontal cortex, amygdala, posterior-, anterior-and lateral-hypothalamus, bed nucleus of the stria terminalis, nucleus basalis of Meynert, thalamus, olfactory bulb, hippocampus or septum. In the latter two brain areas terazosin actually increased behavioral activation suggesting that α 1 -receptors in the septum and hippocampus may inhibit behavior in agreement with the anxiogenic effects of noradrenergic activity in these structures [34] .
The widespread localization of motoric α 1 -receptors in central monoaminergic motivational, motor-and arousalrelated systems suggests that we are dealing with a behavioral activation system that is activated together as a group. This is supported by preliminary data obtained in our laboratory showing that each of the above areas shows a significant increase in the number of fos-positive cells in conditions that produce increased behavioral activity (exposure to a novel cage, injection of modafinil or during the dark photoperiod) 1 .
A series of studies, undertaken by the present authors has provided direct support for the hypothesis that EPI is the transmitter for these receptors. It was found that selective blockade of EPI synthesis by the PNMT inhibitor, DCMB (2, 3-dichloro-α-methylbenzylamine), which has no effect on brainstem NE release [48] , given i.p. to mice or in the LC of rats, produced a marked dose-dependent reduction in behavioral activity in the novel cage test. This reduction was dose-dependently reversed by EPI injected ivt. or within the LC [25] . Moreover, EPI's reversal effect was significantly greater than that of NE and was attenuated by blockade of α 1 -receptors. (EPI is known to have a higher efficacy than NE at central α 1 -receptors controlling phophoinositide metabolism and potentiation of cAMP responses [49] ). In addition, ivt. EPI, but not NE, given alone, produced marked behavioral activation of mice in their home cages during their inactive light phase, an effect that was also attenuated with coinjection of terazosin. Finally, EPI infused in the rat LC has been found to stimulate motor activity and this effect is abolished in animals pretreated with the noradrenergic neurotoxin, DSP4, confirming that the LC is the site of action [Stone, EA, Lin, Y. Unpublished findings]. These findings were also in agreement with reports by other investigators that administration of EPI in the dorsal pons in cats produces EEG arousal [50, 51] .
It is also possible that this is a redundant system. In agreement, it has been found that DSP4 lesion of the dorsal noradrenergic bundle abolishes the behavioral responses to LC injections of α 1 -selective drugs, but does not grossly inhibit behavioral stimulation from sensory input that acts through more widespread channels. This finding suggests that remaining sites of this system can substitute for lesioned areas.
ROLE OF BRAIN EPINEPHRINE AS A POTENTIAL NEUROTRANSMITTER FOR THE BEHAVIO-RALLY-ACTIVATING α 1 -RECEPTORS
A fundamental question regarding motoric α 1 -receptors concerns the identity of their endogenous neurotransmitter. It had been thought that this was norepinephrine (NE) since the latter is the chief α 1 -agonist in the mammalian brain. However, there was also much indirect evidence to suggest that the "minor" brain catecholamine epinephrine (EPI) is the endogenous agonist (reviewed in [25] ). The latter is formed from NE by phenylethanolamine-N-methyltransferase (PNMT) and is present in adrenergic neurons (C1-C3) of the medulla oblongata, which innervate a number of brainstem and limbic structures [35, 36] . It is probably also formed "extraneuronally" from released NE by PNMT located in postsynaptic cells in a number of brain regions. Although
-RECEPTORS AND EPI MAY BE INVOLVED IN POSITIVELY-MOTIVATED BEHAVIORS
A number of experiments have suggested that the increased behavioral activity following central α 1 -receptor stimulation is positively-motivated. Early studies on selfstimulation from the lateral hypothalamus (LH) showed that ivt. EPI facilitated [52] and i.p. DCMB inhibited this positively-motivated behavior [53] . These early studies also showed that i.p. α 1 -receptor antagonists could attenuate or abolish LH self-stimulation [54] [55] [56] . More recent studies using α 1B -knockout mice and ivt. terazosin have shown that the activity of these receptors is also necessary for the motor stimulating effects of a number of positively reinforcing drugs including amphetamine, cocaine, morphine, and modafinil [57] [58] [59] [60] . α 1 -Agonists injected ivt. or in the LC have been found to produce high levels of locomotion and rearing behavior which is similar to the hyperactivity seen after positively reinforcing stimulant drugs or novel cage exposure [10, 33, 61] . We have recently found that ivt. terazosin can abolish the behavioral activity resulting from an ivt. injection of the peptide, orexin, which elicits appetitively motivated activities [62] . Others have shown that α 1B -deficient mice cannot learn a conditioned place preference to morphine [57] while, the present authors have found in a preliminary experiment, that ivt. terazosin blocks behavioral excitation conditioned to the presentation of food in mice [Stone, EA, Lin, Y and Quartermain, D.
Unpublished findings].
are from the PGi [79] , medial PFC and orbitofrontal cortex (OFC) [80] 2 and MPOA [81] . The PFC and OFC are known to process cognitive information related to executive, emotional and reward functions and are believed to excite LC neurons and behavioral activation in anticipation of reward [82] 3 while the MPOA is involved in sexual and possibly circadian functions. α 1 -Receptors, which are known to excite neurons in most other brain regions [29] , are believed to excite LC neurons also based on the findings that pharmacological blockade of α 1 -receptors either in brain slices from adult rats [83] or in vivo in awake dogs [84] significantly reduces resting LC unit firing rate by 50-60%. α 1 -Agonists also produce reliable attenuation of α 2 -adrenoceptor-induced hyperpolarization and GIRK-induced conductance in LC neurons in brain slices [73] .
The excitatory effect of α1-agonist stimulation may be due to a direct postsynaptic action at its receptors and/or a potentiation of the presynaptic release [75] [76] [77] or postsynaptic action of glutamate [83] as these mechanisms have been observed in other brain regions. α 1 -Agonists also may prime glutamate release for several hours after stimulation by activation of protein kinase C [76] . (It should be noted that in previous work by others, EPI and NE were reported to depress LC neuron firing rate via α 2 -adrenoceptors. However, this was observed only under conditions that reduce basal glutamatergic neurotransmission including anesthesia [85, 86] , anesthesia plus an NMDA receptor blocker [87] , and brain slice preparations [88] . However, if glutamate and EPI were released together in the LC by electrical or chemical stimulation of the PGi in anesthetized rats, a very marked increase in LC firing rate was observed [79, 89] . The role of EPI stimulation of α 1 -receptors in this excitation has not yet been examined).
In contrast with the above findings, however, there is evidence that CNS α 1 -receptors under certain conditions can also mediate aversively motivated behavior. Thus α 1 -functional activity in the LC, DR and hypothalamus has been associated with anxiety, fear, stress and corticotrophin releasing factor secretion [63] [64] [65] . Furthermore, peripheral low dose treatment with the α 1 -antagonist, prazosin, has been shown to have anxiolytic effects in the plus-maze and conflict paradigms [66] and to successfully reduce nightmares in PTSD patients [67] . However, an early study showed that inhibition of adrenergic neurotransmission with the α 2 -agonist, clonidine, given i.p. failed to inhibit aversive effects of hypothalamic electrical stimulation [56] . Therefore, it is not yet satisfactorily resolved whether these "motoric" α 1 -receptors are more closely associated with positive or negative motivation.
Whether the EPI/α 1 -system system also interacts with other inputs to the LC including orexin, CRF, ACh and 5HT containing nerve terminals is not known, however, as noted above, preliminary work by the present authors showing that ivt. terazosin can block hyperactivity in mice in the home cage caused by ivt. orexin A, has suggested that such interactions are possible.
PROPOSED NEURAL CIRCUIT OF EPI/α 1 -SYSTEM AT THE LC
With respect to outputs that may affect positivelymotivated behavior, the LC and C1 neurons send NE and EPI containing fibers to a number of regions involved in motor and motivational processes. These include the motor cortex, NAc [90] , VTA, SN [91] , cerebellum, spinal cord and central pattern generators [92] and motoneurons themselves [93] . These areas are both within and downstream of the basal ganglia suggesting that the actions of the EPI/α 1 -system are only partially dependent on dopaminergic neurotransmission.
The presumed neural circuitry of this system at one of its brain sites, the LC, is shown in (Fig. 1) which depicts how this system may integrate various sensory, autonomic and cognitive inputs with motor and motivational outputs. The LC was chosen for the schematic since it contains one of the highest concentrations of α 1 -binding sites in the rodent brain [68] (see Fig. 2) , receives a prominent innervation by EPI containing neurons [69] , has established connections with motor and motivational brain systems and has established roles in both positively-motivated behavior and in depressive etiology and therapy [70] [71] [72] .
α 1 -Receptors in the LC appear to be located in part on its noradrenergic neurons [73] and in part on other structures [74] , possibly glutamatergic nerve endings [75] [76] [77] . The chief EPI input to LC α 1 -receptors arises from the C1 neurons of the nucleus paragigantocellularis (PGi) [69] , which itself has α 1 -receptors [19] . The latter nucleus receives afferent input from sensory, visceral and autonomic related brain regions [78] . The chief glutamatergic inputs to the LC (1) . Schematic summarizing the established and presumed connections of the EPI/α 1 -system at the LC. See text for details. Abbreviations: o.n., output neuron; LC, locus coeruleus; PFC, prefrontal cortex; CRF, corticotrophin releasing factor; ACh, acetylcholine; MPOA, medial preoptic area; PGi, paragigantocellularis nucleus; SN, substantia nigra; VTA, ventral tegmental area; PPN, pedunculopontine nucleus; Sth, subthalamic nucleus; CPG, central pattern generator; NE, norepinephrine; EPI, epinephrine; Glut, glutamate; EA, excitatory amino acid receptor.
It should be noted that the LC also has a very high density of α 2 -adrenoceptors [94] which are also activated by EPI and NE [87, 41] and may function to terminate neuronal excitation. Blockade of α 1 -receptors in the LC by terazosin may therefore lead to an unbalanced α 2 -receptor dominance which would inhibit active behavior. In addition, the PI has proposed that the concomitant stimulation of α 2 -and α 1 -receptors by EPI may serve to prevent a depolarization blockade that may be produced by strong physiological or pharmacological α 1 -receptor stimulation [28] . There are similar colocalizations of high densities of α 1 -and α 2 -adrenoceptors in 3 other regions possessing the EPI/α 1 -system: the DR, MPOA and motor cortex, suggestive of a broader localization of this functional relationship.
nondepressed control levels and are restored by successful treatment with a monoamine oxidase inhibitor [111, 112] . Brain α 1 -receptor function as measured by the cortisol response to amphetamine or desmethylimipramine is significantly blunted [113, 114] . A significant downregulation of α 1 -receptors in the caudate of depressed suicides [115] and in the PFC of alcoholic suicides [116] has been reported by some but others have failed to find these changes [117, 118] . In addition, in animal research most forms of antidepressant agents have been found to enhance either the affinity, density or functional responses of central α 1 -receptors (reviewed in [9] ) while α 1 -antagonists have been found by some [119] [120] [121] , though not by all investigators [122] , to reverse the behavioral actions of antidepressants in animal models of depression and to induce depressive behavior by themselves in these models [123] . The α 1 -agonist, PE, given ivt., was reported to have a positive antidepressant effect in rats in the forced swim test [119] .
Limitations
The LC is one of the major stress-responsive nuclei in the CNS. The present model does not provide a mechanism for distinguishing LC activation related to stress as opposed to positively-motivated behavioral activity. However, others have proposed that it may be a matter of degree in that stress causes maximal activation and bursting in LC neurons with a consequent release of the noradrenergic cotransmitter, galanin, which might mediate certain stress-related behavioral changes [95] . Also the above schematic omits LC outputs to structures that have been implicated in negatively motivated behaviors including the periaqueductal gray, amygdala, septum, hippocampus and bed nucleus of the stria terminalis. As will be discussed below, certain of the latter areas also receive a prominent innervation from the tegmental noradrenergic cell groups (A1, A2) which appear to be more closely related to aversive stimulation and negative motivation [96, 97] .
In addition, the chief stress hormone, corticosterone, which has long been implicated in depression, is known to have a number of actions on the EPI-α 1 -system including facilitating the expression of α 1B -receptors in cell culture [124, 125] , inducing brain PNMT in vivo [126] and at high concentrations, exacerbating the down-regulation of α 1 -receptors by α 1 -agonists [125, 127] .
EFFECTS OF STRESS, DEPRESSION AND HORMONES ON BRAIN α 1 -RECEPTORS AND EPI
We have recently found that corticosterone's action on behavioral activity following stress may be dependent on the state of ongoing activity of the EPI/α 1 -system. If exogenous corticosterone or dexamethasone was administered (via the drinking water) to animals subjected to repeated daily restraint stress, the steroids totally reversed the stressinduced decrease in the activity response to modafinil [105] . However, if the activity response to dark photoperiod was examined, the hormone had the reverse effect, i.e., it aggravated the stress-induced decrease in nocturnal activity 4 Activity during the dark cycle is also dependent on central α 1 -receptor activity [123] . A key difference between nocturnal and daytime physiology in rodents is that central catecholamine systems are far more active at night [128] . We speculate therefore that corticosterone, perhaps by enhancing the rate of brain EPI synthesis and release [126] , pushes the highly active system into depolarization block at night but only enhances its activity during the daytime when it is less active. If this notion is correct, then the clinical effects of this steroid in depression might be dependent on the rate of release of brain EPI and the functional activity of central α 1 -receptors, and may interact with circadian rhythm.
In early studies both stress and depression were found to affect the EPI/α 1 -system at both the pre-and postsynaptic levels. With respect to stress, at the presynaptic level, these studies showed an increase in the turnover of EPI in the LC, C1 and hypothalamic nuclei after footshock stress and a prolonged depletion of brainstem EPI following swimming stress [98, 99] . At the postsynaptic level, in animal research, repeated stress was found to desensitize α 1 -receptors involved either in the potentiation of cAMP responses in cortical and hypothalamic brain slices [100] [101] [102] , or more recently in the modulation of GABA release in the amygdala [103] . Antidepressant treatment reversed the former effect [102] . Severe stress leading to learned helplessness behavior has recently been found to reduce cAMP binding and protein kinase A activity in the frontal cortex and hippocampus [104] . In addition, the present authors have recently shown that repeated stress desensitizes the hyperactivity response to modafinil in mice, which, as discussed above, is dependent on central α 1 -receptor activity [105] . In this regard it has been found that restraint stress in rats markedly lowers the expression of α 1 -receptor mRNA in the midbrain [106, 107] . Other workers have recently shown that, lipopolysaccharide, a potent releaser of cytokines that can induce depression, markedly down-regulates α 1 -receptor density and function in a number of peripheral organs [108, 109] . If it turns out to have the same effect on central α 1 -receptors, this would provide a mechanism by which cytokines potently inhibit active behavior and possibly mood [110] .
REMAINING PROBLEMS
In addition to their action on motor activity, central α 1 -adrenoceptors are also known to be involved in anorexia [129] , anxiety [63, 65] , insomnia [17] , and corticotrophin releasing factor secretion [64, 130] , all of which are increased in typical (though not in atypical) depression. This leads us In depressed patients, two small early studies showed that CSF EPI levels are reduced to a remarkable 30% of to assume that the α 1 -receptors involved in positively motivated behaviors are either on different groups of neurons in the above brain regions or are in different regions altogether from those involved in the latter stress responses. There is some evidence to support this in that the α 1 -receptors involved in the stress responses are probably located in either the paraventricular nucleus of the hypothalamus (anorexia and CRF secretion), amygdala and lateral septal nucleus (anxiety) and basal forebrain (insomnia). It is of interest that these structures receive a significant portion of their innervation from the lateral tegmental groups of noradrenergic neurons (A1-A3, A5 and A7) [131] . Early work suggested a different behavioral function for the LC and lateral tegmental cell groups with the former facilitating active behavior and the latter inhibiting it [132] . It is possible therefore that α 1 -receptors that receive NE from lateral tegmental groups are more involved in stress responses whereas those that receive EPI from the PGi or NE from the LC are more related to positively-motivated behavioral activities. This is supported by a recent study showing that lesion of the ventral noradrenergic bundle which carries fibers from A1 and A2 cell groups to the ventral forebrain abolished the aversiveness of withdrawal from opiate dependence whereas lesion of the dorsal noradrenergic bundle did not have this effect [96] . Further research on the regulation of these receptors by their presumptive inputs will be necessary to clarify this question.
CNS during successful adaptation to chronic stress and antidepressant therapy to yield adaptive changes in neural output or plasticity brought about by the actions of growth factors [136] [137] [138] [139] [140] [141] . In support, α 1 -receptor activation has been shown to stimulate both the expression of immediate early genes in the cortex, limbic system and brainstem during stress [142, 143] as well as the phosphorylation of cortical MAP kinase (MAPK) [144] which is involved in growth factor signaling processes. As noted above, in preliminary experiments modafinil has been found to activate MAPK in cell culture as well as in vivo in the mouse cerebral cortex and to do so via stimulation of α 1 -receptors. It has also been found that administration of an α 2 -antagonist, yohimbine, which facilitates the release of brain catecholamines, increases the expression of nerve growth factor mRNA in the rat cortex [145] while catecholamines and/or indoleamines in cell culture [146] as well as electroconvulsive shock and antidepressant drugs in vivo, which enhance central noradrenergic neurotransmission [137] , can induce the expression of BDNF, GDNF and/or NT3 as well as elicit functional and neuroanatomical signs of neural plasticity [147] . Very recently it has been reported that α 1 -adrenoceptors are involved in neurogenesis in the rat hippocampus, a process that may be intimately related to depression and antidepressant actions [141, 148, 139] , and it is known that the human dentate gyrus contains an unusually high density of these receptors [149] .
If the EPI-α 1 -system is impaired in depression, as we have proposed, then this may be a factor not only in the reduced behavioral activity of depressives but also in the neuronal atrophy and loss of glial cells in the hippocampus [150] and prefrontal cortex [151] , respectively, that occur in these patients. However, it has been found recently that the overexpression of constitutively active mutant α 1 -receptors causes neuronal degeneration in the mouse brain [152] indicating the need for careful dose-response studies to fully clarify the role of these receptors in brain trophic and atrophic processes. Further research will be necessary to define the mechanism of these changes and to determine how they are related to long-term changes in behavior and chronic stress 6 .
A second remaining issue concerns the action of modafinil on central α 1 -receptors. As discussed above, modafinil produces a potent increase in exploration and grooming behavior in rodents which is totally dependent on central α 1 -adrenoceptor activity. As such, the drug may be useful in studying the responsiveness of behaviorallyactivating brain α 1 -receptors in various patient populations in order to detect functional abnormalities in neurotransmission. Whether or not modafinil is an agonist at α 1 -receptors, however, is still unclear. The compound does not activate and may inhibit phosphatidylinositol hydrolysis in mouse cortical brain slices yet it does stimulate a prazosin-or terazosin-reversible phosphorylation of MAPK both in vitro and in vivo 5 however, the in vitro response was obtained only at fairly high concentrations (10 -4 M). The drug also appears to act on other neuronal systems including orexin, DA, and GABA neurons [133, 134] .
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